MAP 30: a new inhibitor of HIV‐1 infection and replication

FEBS Letters

Lee-Huang, Sylvia⁵  Huang, Philip L.³  Chen, Hao-Chia⁴  Huang, Henry I.³  Kung, Hsiang-fu²  Huang, Paul L.³  Huang, Peter³  Nara, Peter L.¹ 

[1] Laboratory of Tumor Cell Biology, National Cancer Institute-Frederick Cancer Research Facility, Frederick, MD 21701, USA;Laboratory of Biochemical Physiology, National Cancer Institute-Frederick Cancer Research Facility, Frederick, MD 21701, USA;American Biosciences, New York, NY 10021, USA;Endocrinology and Reproduction Research Branch, National Institute of Child Health and Human Development, Bethesda, MD 20892, USA;Department of Biochemistry, New York University School of Medicine, New York, NY 10016, USA

关键词: Plant protein;    Antiviral agent;    AIDS;   

DOI  :  10.1016/0014-5793(90)80438-O

学科分类：生物化学/生物物理

来源: John Wiley & Sons Ltd.

【 摘 要 】

A new inhibitor of human immunodeficiency virus (HIV) has been isolated and purified to homogeneity from the seeds and fruits of the Momordica charantia. This compound, MAP 30 (Momordica Anti-HIV Protein), is a basic protein of about 30 kDa. It exhibits dose-dependent inhibition of cell-free HIV-1 infection and replication as measured by: (i) quantitative focal syncytium formation on CEM-ss monolayers; (II) viral core protein p24 expression; and (iii) viral-associated reverse transcriptase (RT) activity in HIV-1 infected H9 cells. The doses required for 50% inhibition (ID₅₀) in these assays were 0.83, 0.22 and 0.33 nM, respectively. No cytotoxic or cytostatic effects were found under the assay conditions. These data suggest that MAP 30 may be a useful therapeutic agent in the treatment of HIV-1 infections. The sequence of the N-terminal 44 amino acids of MAP 30 has been determined.

【 授权许可】

Unknown